Universe Pharmaceuticals Net Worth

Universe Pharmaceuticals Net Worth Breakdown

  UPC
The net worth of Universe Pharmaceuticals is the difference between its total assets and liabilities. Universe Pharmaceuticals' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Universe Pharmaceuticals' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Universe Pharmaceuticals' net worth can be used as a measure of its financial health and stability which can help investors to decide if Universe Pharmaceuticals is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Universe Pharmaceuticals stock.

Universe Pharmaceuticals Net Worth Analysis

Universe Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Universe Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Universe Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Universe Pharmaceuticals' net worth analysis. One common approach is to calculate Universe Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Universe Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Universe Pharmaceuticals' net worth. This approach calculates the present value of Universe Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Universe Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Universe Pharmaceuticals' net worth. This involves comparing Universe Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Universe Pharmaceuticals' net worth relative to its peers.
To determine if Universe Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Universe Pharmaceuticals' net worth research are outlined below:
Universe Pharmaceuticals generated a negative expected return over the last 90 days
Universe Pharmaceuticals has high historical volatility and very poor performance
Universe Pharmaceuticals has some characteristics of a very speculative penny stock
Universe Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the last year's revenue of 32.31 M. Reported Net Loss for the year was (6.16 M) with profit before taxes, overhead, and interest of 7.56 M.
Latest headline from gurufocus.com: Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed ...
Universe Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Universe Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Universe Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
9th of February 2024
Upcoming Quarterly Report
View
30th of September 2023
Next Fiscal Quarter End
View

Know Universe Pharmaceuticals' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Universe Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Universe Pharmaceuticals backward and forwards among themselves. Universe Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Universe Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Anson Funds Management Lp2024-12-31
230.4 K
Quadrature Capital Llp2024-09-30
24.9 K
Virtu Financial Llc2024-09-30
16.6 K
Morgan Stanley - Brokerage Accounts2024-12-31
65.0
Millennium Management Llc2024-12-31
0.0
Renaissance Technologies Corp2024-12-31
0.0
Mml Investors Services Inc2024-12-31
0.0
Xtx Topco Ltd2024-12-31
0.0
Two Sigma Securities, Llc2024-12-31
0.0
Ubs Group Ag2024-12-31
0.0
Note, although Universe Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Universe Pharmaceuticals' market capitalization trends

The company currently falls under 'Nano-Cap' category with a total capitalization of 1.94 M.

Market Cap

0.0

Project Universe Pharmaceuticals' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.12)(0.13)
Return On Capital Employed(0.10)(0.10)
Return On Assets(0.12)(0.13)
Return On Equity(0.18)(0.17)
The company has Net Profit Margin of (0.69) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.14) %, which entails that for every $100 of revenue, it lost $0.14.
When accessing Universe Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Universe Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Universe Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Universe Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Universe Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Universe Pharmaceuticals' management manipulating its earnings.

Evaluate Universe Pharmaceuticals' management efficiency

Universe Pharmaceuticals has Return on Asset of (0.0565) % which means that on every $100 spent on assets, it lost $0.0565. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.5022) %, meaning that it generated no profit with money invested by stockholders. Universe Pharmaceuticals' management efficiency ratios could be used to measure how well Universe Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of March 1, 2025, Return On Tangible Assets is expected to decline to -0.13. The current year's Return On Capital Employed is expected to grow to -0.1. At present, Universe Pharmaceuticals' Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.01, whereas Total Assets are forecasted to decline to about 47.2 M.
Last ReportedProjected for Next Year
Book Value Per Share 9.82  6.59 
Tangible Book Value Per Share 9.78  6.56 
Enterprise Value Over EBITDA(18.55)(17.62)
Price Book Value Ratio 1.50  1.43 
Enterprise Value Multiple(18.55)(17.62)
Price Fair Value 1.50  1.43 
Effective leadership at Universe Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Enterprise Value Revenue
0.0174
Revenue
26.7 M
Quarterly Revenue Growth
(0.30)
Revenue Per Share
110.271
Return On Equity
(0.50)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Universe Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Universe Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Universe Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Universe Pharmaceuticals time-series forecasting models is one of many Universe Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Universe Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Universe Pharmaceuticals Earnings per Share Projection vs Actual

When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Universe Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.82)
Earnings Share
(76.35)
Revenue Per Share
110.271
Quarterly Revenue Growth
(0.30)
Return On Assets
(0.06)
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Universe Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.